[HTML][HTML] The Long-Term Benefit of Sacubitril/Valsartan in Patients with HFrEF: A 5-Year Follow-Up Study in a Real World Population
G Dattilo, G Laterra, R Licordari, F Parisi… - Journal of Clinical …, 2023 - mdpi.com
Heart failure (HF) is a progressive condition with an increasing prevalence, and the scientific
evidence of heart failure with reduced ejection fraction (HFrEF) reports a 6% rate of 1-year …
evidence of heart failure with reduced ejection fraction (HFrEF) reports a 6% rate of 1-year …
[HTML][HTML] The Long-Term Benefit of Sacubitril/Valsartan in Patients with HFrEF: A 5-Year Follow-Up Study in a Real World Population
G Dattilo, G Laterra, R Licordari, F Parisi… - Journal of Clinical …, 2023 - ncbi.nlm.nih.gov
Heart failure (HF) is a progressive condition with an increasing prevalence, and the scientific
evidence of heart failure with reduced ejection fraction (HFrEF) reports a 6% rate of 1-year …
evidence of heart failure with reduced ejection fraction (HFrEF) reports a 6% rate of 1-year …
The Long-Term Benefit of Sacubitril/Valsartan in Patients with HFrEF: A 5-Year Follow-Up Study in a Real World Population
G Dattilo, G Laterra, R Licordari, F Parisi… - Journal of Clinical …, 2023 - search.proquest.com
Heart failure (HF) is a progressive condition with an increasing prevalence, and the scientific
evidence of heart failure with reduced ejection fraction (HFrEF) reports a 6% rate of 1-year …
evidence of heart failure with reduced ejection fraction (HFrEF) reports a 6% rate of 1-year …
The Long-Term Benefit of Sacubitril/Valsartan in Patients with HFrEF: A 5-Year Follow-Up Study in a Real World Population.
G Dattilo, G Laterra, R Licordari, F Parisi… - Journal of Clinical …, 2023 - europepmc.org
Methods Seventy consecutive patients with HFrEF and eligible for ARNI, according to
PARADIGM-HF criteria, were enrolled. All patients had an overall follow-up of 60 months …
PARADIGM-HF criteria, were enrolled. All patients had an overall follow-up of 60 months …
The Long-Term Benefit of Sacubitril/Valsartan in Patients with HFrEF: A 5-Year Follow-Up Study in a Real World Population.
G Dattilo, G Laterra, R Licordari… - Journal of Clinical …, 2023 - search.ebscohost.com
Heart failure (HF) is a progressive condition with an increasing prevalence, and the scientific
evidence of heart failure with reduced ejection fraction (HFrEF) reports a 6% rate of 1-year …
evidence of heart failure with reduced ejection fraction (HFrEF) reports a 6% rate of 1-year …
The Long-Term Benefit of Sacubitril/Valsartan in Patients with HFrEF: A 5-Year Follow-Up Study in a Real World Population
G Dattilo, G Laterra, R Licordari… - Journal of clinical …, 2023 - pubmed.ncbi.nlm.nih.gov
Heart failure (HF) is a progressive condition with an increasing prevalence, and the scientific
evidence of heart failure with reduced ejection fraction (HFrEF) reports a 6% rate of 1-year …
evidence of heart failure with reduced ejection fraction (HFrEF) reports a 6% rate of 1-year …